Explore our FDA-approved Shield™ blood-based screening test. Discover how our advanced technology detects cancer early, when it's most treatable.

Explore the SHIELD study, a prospective, observational trial focusing on screening for high frequency malignant diseases.

Guardant Health’s vision is to transform cancer care across all stages of the disease through the power of blood. The continuum of care includes patients with early-stage and advanced cancer, as well as asymptomatic individuals.

Jun 11, 2024 · The Shield test is a qualitative in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Blood Collection Kit. Shield is intended for colorectal cancer screening in individuals at average risk of the disease, aged 45 years or older.

Jul 29, 2024 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. It is the first ...

May 2, 2022 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC).

Aug 1, 2024 · Shield outperforms two guideline-recommended stool-based tests, fecal immunochemical test (FIT) and the multi-target stool DNA (mtsDNA) test when considering life years gained (214 vs. 157 and 199) and CRC cases averted (27 vs. 16 and 22). Shield also prevents more deaths from CRC (13 vs. 7 and 11). 5

Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.

Jan 30, 2025 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Centre (ADPHC) to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant’s Shield™ test.

Feb 20, 2025 · Received Medicare coverage for Guardant Reveal on Smart Liquid Biopsy platform for colorectal cancer surveillance; Shield selected by NIH for inclusion in the Vanguard multi cancer detection study based on strong feasibility data in predicting presence of ten cancer types and cancer site of origin